Amir Noeparast

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib

Amir Noeparast, Erik Teugels, Philippe Giron et al. · Oncotarget · 2016 · 100 citations · Full text

Braf Kinase Activity, Impaired Braf Kinases, Pathology +17

Synthesis and analgesic activity of new 1,3,4-oxadiazoles and 1,2,4-triazoles

Ali Almasirad, Abbas Shafiee, Mohammad Abdollahı et al. · Medicinal Chemistry Research · 2010 · 45 citations

Medicinal Chemistry, Medicine, New 1,3,4-Oxadiazoles +6

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer

Amir Noeparast, Philippe Giron, Sylvia De Brakeleer et al. · Oncotarget · 2018 · 31 citations · Full text

CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition

Amir Noeparast, Philippe Giron, Alfiah Noor et al. · Oncogene · 2019 · 29 citations · Full text

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer

Ijeoma Adaku Umelo, Amir Noeparast, Gang Chen et al. · Oncotarget · 2015 · 22 citations · Full text